Kura Oncology (NASDAQ:KURA) Price Target Cut to $28.00 by Analysts at Jefferies Financial Group

Kura Oncology (NASDAQ:KURA) had its target price lowered by Jefferies Financial Group from $32.00 to $28.00 in a research report report published on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms have also issued reports on KURA. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. JMP Securities reissued a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday, November 19th. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and cut their price target for the company from $26.00 to $19.00 in a report on Monday, October 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Stock Performance

NASDAQ KURA opened at $10.80 on Thursday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $9.06 and a fifty-two week high of $24.17. The business has a fifty day moving average of $17.88 and a 200-day moving average of $19.69. The stock has a market cap of $839.81 million, a price-to-earnings ratio of -4.58 and a beta of 0.86.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after acquiring an additional 41,535 shares during the last quarter. Barclays PLC grew its holdings in shares of Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after purchasing an additional 84,563 shares during the period. Jane Street Group LLC increased its position in Kura Oncology by 36.7% during the 3rd quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock worth $2,464,000 after purchasing an additional 33,848 shares in the last quarter. Point72 DIFC Ltd purchased a new position in Kura Oncology in the third quarter valued at approximately $146,000. Finally, Point72 Asset Management L.P. acquired a new position in Kura Oncology during the third quarter valued at approximately $3,695,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.